Pharming Group (NL:PHARM)

:PHARM

PHARM

Pharming Group

RESEARCH TOOLSreports

Want to see NL:PHARM full AI Analyst Report?

Pharming Group (PHARM) Earnings Dates, Call Summary & Reports

Q: What is the P/E ratio of Pharming Group stock?

The P/E ratio of {name} is N/A.

26 Followers

Earnings Data

Report Date

Jul 30, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

<0.01

Last Year’s EPS

<0.01

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:May 07, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call balanced short-term headwinds (an expected RUCONEST revenue decline driven by inventory normalization, ex-U.S. exits and early competitive impacts; a near-term Q2 revenue risk; and some cash/one-time lease impacts) with several substantial positives: strong 34% YoY growth in Joenja, continued patient and prescriber additions for RUCONEST, successful regulatory progress (pediatric resubmission, CHMP positive opinion), upcoming Phase II readouts and napazimone enrollment completion, positive operating cash flow, and continued cost discipline. Management reaffirmed full-year guidance and emphasized pipeline catalysts and durable cash generation, indicating confidence in a return to growth in H2 2026 and beyond.

Company Guidance

Pharming reaffirmed full‑year 2026 revenue guidance of $405–$425 million (growth ~8–13% vs. 2025), anchored by a mid‑point assumption of low‑single‑digit RUCONEST growth; Q1 revenues were $72.4M (‑8% YoY) with RUCONEST down 15% YoY (an ~8% expected inventory normalization headwind consistent with prior 7–9% guidance plus ~3% from the planned ex‑U.S. exit) and Joenja revenues of $14.1M (+34% YoY). Management expects continued RUCONEST pressure into Q2 with recovery in H2 as inventories rebuild, gross margin ≈90%, operating expenses of $330–335M (including $60M incremental R&D and up to $30M for napazimone), positive Q1 operating cash flow of $2M, cash & marketable securities of $171.8M (down $9.3M), no $10M commercial milestone assumed this year, and accelerating Joenja growth (>10 percentage points vs. 2025) supported by U.S. pediatric sNDA resubmission (40/50 mg submitted; FDA ~6‑month review) and planned European (Germany Q2) and Japan (August) launches.

Total Q1 Revenue and Guidance Reaffirmed

Q1 2026 revenue of $72.4M (down 8% YoY) with full-year 2026 revenue guidance reaffirmed at $405M–$425M, implying ~8%–13% growth vs. 2025.

Strong Joenja Growth

Joenja revenue grew 34% YoY to $14.1M globally. U.S. paid patients reached 127 (up 25% YoY), net adds accelerated to 7 patients in the quarter and U.S. fill rate remained high at 85%.

RUCONEST Franchise Durability and New Prescribers

RUCONEST added ~50 new patient enrollments and 23 new prescribers in Q1, and management reports the overwhelming majority of RUCONEST patients have remained on therapy nine months after a new oral competitor launch.

Regulatory and Geographic Progress for Joenja

Meaningful regulatory progress: resubmission of pediatric sNDA (40 mg & 50 mg) in April with FDA decision expected in ~6 months; CHMP positive opinion obtained and Germany launch planned this year; Japan launch anticipated in August.

Pipeline Catalysts and Clinical Momentum

Two Phase II readouts for leniolisib in higher-prevalence PIDs are expected later this year; napazimone registrational study enrollment expected to complete in 2026 with readout in 2027; expanded access CVID data (n=6) show consistent clinical improvement and biomarker modulation.

Positive Operating Cash Flow and Strong Cost Discipline

Positive operating cash flow of $2.0M in Q1; total operating expenses down 9% YoY (flat after adjusting for one-time 2025 acquisition costs); company expects operating expenses $330M–$335M for 2026 and cites $9M benefit from prior 20% G&A headcount reduction.

Healthy Balance Sheet to Support Pipeline

Total cash and marketable securities of $171.8M at quarter-end and management expects available cash plus future operating cash flows to fully support planned pipeline and prelaunch activities.

Pharming Group (NL:PHARM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NL:PHARM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 30, 2026	2026 (Q2)	<0.01 / -	0.005	―	―	―
May 07, 2026	2026 (Q1)	0.00 / >-0.01	-0.019	68.18% (+0.01)
Mar 12, 2026	2025 (Q4)	<0.01 / <0.01	0.004	40.00% (<+0.01)
Nov 06, 2025	2025 (Q3)	0.00 / <0.01	-0.002	600.00% (+0.01)
Jul 31, 2025	2025 (Q2)	>-0.01 / <0.01	-0.002	400.00% (<+0.01)
May 08, 2025	2025 (Q1)	>-0.01 / -0.02	-0.016	-15.79% (>-0.01)
Mar 13, 2025	2024 (Q4)	<0.01 / <0.01	-0.003	225.00% (<+0.01)
Oct 24, 2024	2024 (Q3)	0.00 / >-0.01	0	―
Aug 01, 2024	2024 (Q2)	0.00 / >-0.01	<0.001	-300.00% (>-0.01)
May 08, 2024	2024 (Q1)	<0.01 / -0.02	-0.015	-11.76% (>-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NL:PHARM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2026	€1.40	€1.03	-25.81%
Mar 12, 2026	€1.37	€1.33	-3.42%
Nov 06, 2025	€1.10	€1.37	+24.25%
Jul 31, 2025	€0.85	€0.97	+14.15%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pharming Group (NL:PHARM) report earnings?

Pharming Group (NL:PHARM) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).

What is Pharming Group (NL:PHARM) earnings time?

Pharming Group (NL:PHARM) earnings time is at Jul 30, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Pharming Group stock?

The P/E ratio of Pharming Group is N/A.

What is NL:PHARM EPS forecast?

NL:PHARM EPS forecast for the fiscal quarter 2026 (Q2) is <0.01.